The Effects of Lacosamide on Patients With Chronic Migraine: A Randomized, Double‐Blind, Clinical Trial
Abstract
Purpose: Calcitonin gene‐related peptide (CGRP) is a key peptide released during trigeminal system‐initiated migraine attacks. Evidence suggests that lacosamide can inhibit CGRP release. This study aimed to assess the effectiveness of lacosamide in patients with chronic migraine.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.